OWC Pharmaceutical Research Corp (OWCP)

[stockfan100]

Specific news will either stop or prevent many of these arguments.

Unfortunately, that won’t happen until OWCP is in dollars and on the NASDAQ and that time of course will come!
Here is why baseless arguments don’t go away till then. We already have “specific news” but the misinformation and fake news about the company still continues.

For example, both the company and the SEC already clearly stated that the SEC’s investigation is not about the company and is about JF. And, the fact that the company is still allowed to be traded on the market after about one year into the JF investigation is a proof of that.
But, you can see the baseless jokes about company in this regard still continues. …well ….until OWCP is in dollars and on NASDAQ, of course!

Here are the “specific news” that company is not involved in SEC’s JF investigation as a defendant...both from SEC and from OWCP!

From SEC:

"The SEC’s complaint charges Friedland, Global Corporate Strategies LLC, and Intiva Pharma LLC with violations of Sections 17(a) and (b) of the Securities Act of 1933 and Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5. The SEC is seeking injunctions, disgorgement, prejudgment interest, penalties, and penny stock bars. The complaint also named Kathy B. Friedland, Lane 6552 LLC, Aspen Upper Ranch LLC, Assurance Management, LLC, and the Jeffrey and Kathy Friedland Irrevocable Trust as relief defendants."

From SEC:

SEC Obtains Partial Asset Freeze of Proceeds in Alleged Fraudulent Touting Scheme
Litigation Release No. 24066 / March 8, 2018
Securities and Exchange Commission v. Jeffrey O. Friedland, Global Corporate Strategies LLC, and Intiva Pharma LLC, Defendants, and Lane 6552 LLC, Kathy B. Friedland, Aspen Upper Ranch LLC, Assurance Management, LLC, and The Jeffrey and Kathy Friedland Irrevocable Trust, Relief Defendants , Case. No. 1:18-cv-00529 (D. Colo. Filed March 5, 2018)

The SEC's complaint, which was filed on March 5 in federal district court in Denver, alleges that Colorado resident Jeffrey O. Friedland touted OWC Pharmaceutical Research Corp. while misrepresenting both his own investment in OWC and the true nature of his professional relationship with the company.

https://www.sec.gov/litigation/litreleases/2018/lr24066.htm


From OWCP:

As we have stated in our 8-K filing of today, we are neither a party to the pending SEC action against a former adviser to the Company, nor is the Company alleged to have been a party to nor had any knowledge of the purported scheme by the former adviser, who is the subject of the SEC action.
The Company's management is committed to and focused on our development programs which are continuing as per plan. These include inter alia, our current safety trial for our cannabis cream; the approval processes to initiate a safety trial for our oral disintegrating tablet and additional pipeline projects.

As a management team, we are committed to building value for our shareholders though professional, ethical and strategic management of a technology platform that we believe will bring improved health and quality of life to millions of patients around the world. We have recently announced the addition of our new Chief Scientific Officer and we continue to develop the resources we believe will bolster our endeavors in creating a great company.

Yours sincerely,

Dr. Stanley Hirsch
Chairman of the Board